Acromegaly  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
NCT01673646: Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Completed
2
33
Japan
Pasireotide LAR, SOM230
Novartis Pharmaceuticals
Acromegaly, Pituitary Gigantism
04/17
04/17

Download Options